Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation
- 1 January 2012
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 18 (19), 2408-2414
- https://doi.org/10.3748/wjg.v18.i19.2408
Abstract
To investigate the diagnostic value of glypican-3 (GPC3) and its relationship with hepatocellular carcinoma (HCC) recurrence after liver transplantation.HCC tissue samples (n = 31) obtained from patients who had undergone liver transplantation were analyzed. GPC3 mRNA and protein expression were analyzed by TaqMan real-time reverse transcription-polymerase chain reaction and immunohistochemistry. Correlation between the GPC3 expression and clinicopathological features was analyzed. The potential prognostic value of GPC3 was investigated by comparing recurrence-free survival between HCC patients with and without GPC3 expression.Using a cutoff value of 3.5 × 10⁻², 20 of 31 cancerous tissues had expression values of > 3.5 × 10⁻², whereas 3 of 31 adjacent non-neoplastic parenchyma and 0 of 20 control liver tissues had expression values of > 3.5 × 10⁻² (P < 0.001). GPC3 protein was immunoexpressed in 68% of cancerous tissues, but not in adjacent non-neoplastic parenchyma and control liver tissues. Vascular invasion was significantly related to GPC3 expression (P < 0.05). Recurrence-free survival was significantly longer for patients without GPC3 mRNA overexpression (> 3.5 × 10⁻²) and those without vascular invasion (P < 0.05 for both).GPC3 expression may serve as a valuable diagnostic marker for HCC. GPC3 mRNA overexpression may be an adverse indicator for HCC patients after liver transplantation.Keywords
This publication has 29 references indexed in Scilit:
- Recurrence and Poor Prognosis Following Resection of Small Hepatitis B-Related Hepatocellular Carcinoma Lesions Are Associated with Aberrant Tumor Expression Profiles of Glypican 3 and OsteopontinAnnals of Surgical Oncology, 2011
- Current controversies surrounding liver transplantation for hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2010
- Utility of glypican‐3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine‐needle aspiration biopsiesDiagnostic Cytopathology, 2009
- Anti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver CancerCancer Research, 2008
- Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?European Journal of Surgical Oncology, 2008
- Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesisWorld Journal of Gastroenterology, 2008
- Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?The American Journal of Gastroenterology, 2006
- Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt SignalingCancer Research, 2005
- Glypican‐3 is overexpressed in human hepatocellular carcinomaCancer Science, 2003
- Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signalingInternational Journal of Cancer, 2002